Your browser doesn't support javascript.
loading
Targeting chemokines for acute lymphoblastic leukemia therapy.
Hong, Zixi; Wei, Zimeng; Xie, Tian; Fu, Lin; Sun, Jiaxing; Zhou, Fuling; Jamal, Muhammad; Zhang, Qiuping; Shao, Liang.
Afiliação
  • Hong Z; Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Wei Z; Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, China.
  • Xie T; Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, China.
  • Fu L; The First Clinical School of Wuhan University, Wuhan, China.
  • Sun J; Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, China.
  • Zhou F; Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Jamal M; Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, China.
  • Zhang Q; Department of Immunology, School of Basic Medical Science, Wuhan University, Wuhan, China. qpzhang@whu.edu.cn.
  • Shao L; Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China. liangsmd@163.com.
J Hematol Oncol ; 14(1): 48, 2021 03 20.
Article em En | MEDLINE | ID: mdl-33743810
ABSTRACT
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by the malignant clonal expansion of lymphoid hematopoietic precursors. It is regulated by various signaling molecules such as cytokines and adhesion molecules in its microenvironment. Chemokines are chemotactic cytokines that regulate migration, positioning and interactions of cells. Many chemokine axes such as CXCL12/CXCR4 and CCL25/CCR9 have been proved to play important roles in leukemia microenvironment and further affect ALL outcomes. In this review, we summarize the chemokines that are involved in ALL progression and elaborate on their roles and mechanisms in leukemia cell proliferation, infiltration, drug resistance and disease relapse. We also discuss the potential of targeting chemokine axes for ALL treatments, since many related inhibitors have shown promising efficacy in preclinical trials, and some of them have entered clinical trials.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocinas / Leucemia-Linfoma Linfoblástico de Células Precursoras / Microambiente Tumoral / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimiocinas / Leucemia-Linfoma Linfoblástico de Células Precursoras / Microambiente Tumoral / Antineoplásicos Limite: Animals / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article